Fresenius SE & Co. KGaA · XETR:FRE
Fresenius SE & Co. KGaA — Fresenius — Shareholder Meeting (May 2008)
15 slides from Fresenius SE & Co. KGaA's shareholder meeting presentation, May 21, 2008
Slide 1: Annual General Meeting Fresenius SE Welcome
Annual General Meeting Fresenius SE Welcome May 21, 2008
Slide 2: Agenda
Agenda I. Financial Results 2007 II. Share Price Development III. 1st Quarter 2008 IV. Outlook FY/2008 Annual General Meeting Fresenius SE, Investor Relations © Copyright, May 21, 2008 Page 2
Slide 3: Profitable Growth in Attractive Segments of the Health Care Market
Profitable Growth in Attractive Segments of the Health Care Market Fresenius Biotech Antibodies/ Immunology Fresenius Fresenius Fresenius Fresenius Medical Care Kabi Helios Vamed Dialysis Equipment Infusion and Hospital Operation Engineering and and Services Nutrition Therapy Services Annual General
Slide 4: Fresenius Group: Strong Financial Results
Fresenius Group: Strong Financial Results €m 11,358 Sales 10,777 +10 % cc 7,889 1,609 EBIT 7,271 1,444 5-yrs-CAGR: 13 % 7,064 +17 % cc 969 781 845 410 Net 5-yrs-CAGR: 20 % 330 +28 % cc Income 222 168 115 5-yrs-CAGR: 37 % cc: constant currency 2003 2004 2005 2006 2007 CAGR: Compound annual growth rat
Slide 5: Fresenius SE: ~15% Dividend Increase Proposed
Fresenius SE: ~15 % Dividend Increase Proposed € 0.67 0.58 - Proposed dividend: 0.50 € 0.66 per ordinary share 0.46 0.42 € 0.67 per preference share 0.39 0.35 0.32 - 15th consecutive dividend 0.27 increase - Total distribution: € 103.2 m 1999 2000 2001 2002 2003 2004 2005 2006 2007 Proposal Annual G
Slide 6: Fresenius Share Price Development in 2007
Fresenius Share Price Development in 2007 Relative share price performance Share price increase December 29, 2007 = 100 Fresenius 130 ordinary share: +11 % 120 Fresenius Pref. preference share: +5 % 110 Ord. MDAX 100 MDAX: +5 % 90 12/31/06 03/31/07 06/30/07 09/30/07 12/31/07 MDAX Fresenius SA Fresen
Slide 7: Fresenius Group: Successful Start into 2008
Fresenius Group: Successful Start into 2008 Sales EBIT Net income Q1/08 € 2,798 m € 377 m € 100 m Growth at constant 8% 7% 13 % currency rates Growth at actual 1% -1 % 8% currency rates Annual General Meeting Fresenius SE, Investor Relations © Copyright, May 21, 2008 Page 7
Slide 8: Fresenius Medical Care: Financial Results and Outlook
Fresenius Medical Care: Financial Results and Outlook 1st Quarter 2008 Sales US$ 2,512 m growth +8 % Net income US$ 186 m growth +16 % Outlook FY/2008 Sales > US$ 10.4 bn Net income US$ 805 – 825 m US GAAP Annual General Meeting Fresenius SE, Investor Relations © Copyright, May 21, 2008 Page 8
Slide 9: Fresenius Kabi: Financial Results and Outlook
Fresenius Kabi: Financial Results and Outlook 1st Quarter 2008 Sales € 545 m growth +13 % EBIT € 87 m growth +13 % Outlook FY/2008 Sales growth (in constant currency) 12 – 15 % EBIT margin ~16.5 % US GAAP Annual General Meeting Fresenius SE, Investor Relations © Copyright, May 21, 2008 Page 9
Slide 10: Fresenius Helios: Financial Results and Outlook
Fresenius Helios: Financial Results and Outlook 1st Quarter 2008 Sales € 509 m growth +16 % EBIT € 38 m growth +19 % Outlook FY/2008 Sales > € 2,050 m EBIT € 160 – 170 m US GAAP Annual General Meeting Fresenius SE, Investor Relations © Copyright, May 21, 2008 Page 10
Slide 11: Fresenius Vamed: Financial Results and Outlook
Fresenius Vamed: Financial Results and Outlook 1st Quarter 2008 Sales € 74 m growth +1 % EBIT €4m growth -20 % Outlook FY/2008 Sales growth 5 – 10 % EBIT growth 5 – 10 % US GAAP Prince Court Medical Center, Kuala Lumpur Annual General Meeting Fresenius SE, Investor Relations © Copyright, May 21, 200
Slide 12: Fresenius Group: Positive Outlook for 2008
Fresenius Group: Positive Outlook for 2008 Guidance Revenue growth 8 - 10 % in constant currency Net income growth in constant currency 10 - 15 % Capex ~ € 750 m US GAAP Annual General Meeting Fresenius SE, Investor Relations © Copyright, May 21, 2008 Page 12
Slide 13: Fresenius Group: Sustained profitable growth
Fresenius Group: Sustained profitable growth - Leading position in non-cyclical markets with sustainable growth - Industry-leading organic growth in all business segments - International expansion drives organic growth - Diversified Group sales and earnings base - Successful acquisition history - Pr
Slide 14: Thank you for your attention
Annual General Meeting Fresenius SE Thank you for your attention May 21, 2008
Slide 15: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive